Literature DB >> 28754713

UBAP2L is amplified in a large subset of human lung adenocarcinoma and is critical for epithelial lung cell identity and tumor metastasis.

Romain Aucagne1, Simon Girard1, Nadine Mayotte1, Bernhard Lehnertz1, Stéphane Lopes-Paciencia1, Patrick Gendron2, Geneviève Boucher2, Jalila Chagraoui1, Guy Sauvageau3,4,5.   

Abstract

The ubiquitin-associated protein 2-like (UBAP2L) gene remains poorly studied in human and mouse development. UBAP2L interacts with the Polycomb group protein B lymphoma Mo-MLV insertion region 1 homolog (BMI1) and determines the activity of mouse hematopoietic stem cells in vivo Here we show that loss of Ubap2l leads to disorganized respiratory epithelium of mutant neonates, which die of respiratory failure. We also show that UBAP2L overexpression leads to epithelial-mesenchymal transition-like phenotype in a non-small cell lung carcinoma (NSCLC) cell line. UBAP2L is amplified in 15% of human primary lung adenocarcinoma specimens. Such patients express higher levels of UBAP2L and show a reduction in survival when compared with those who do not have this gene amplification. Supporting a possible role for UBAP2L in lung tumor progression, NSCLC cells engineered to express low levels of this gene produce much smaller tumors in vivo than wild-type control cells. Together, these results suggest that UBAP2L contributes to epithelial lung cell identity in mice and that it plays an important role in human lung adenocarcinoma.-Aucagne, R., Girard, S., Mayotte, N., Lehnertz, B., Lopes-Paciencia, S., Gendron, P., Boucher, G., Chagraoui, J., Sauvageau, G. UBAP2L is amplified in a large subset of human lung adenocarcinoma and is critical for epithelial lung cell identity and tumor metastasis. © FASEB.

Entities:  

Keywords:  EMT-like phenotype; UBAP2L; metastasis; non-small cell lung cancer

Mesh:

Substances:

Year:  2017        PMID: 28754713     DOI: 10.1096/fj.201601219RRR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  7 in total

Review 1.  Ubiquitin Binding Protein 2-Like (UBAP2L): is it so NICE After All?

Authors:  Lucile Guerber; Evanthia Pangou; Izabela Sumara
Journal:  Front Cell Dev Biol       Date:  2022-06-20

2.  MicroRNA-19a-3p inhibits the cellular proliferation and invasion of non-small cell lung cancer by downregulating UBAP2L.

Authors:  Yuejiang Pan; Ke Jin; Xuan Xie; Kexi Wang; Huizhong Zhang
Journal:  Exp Ther Med       Date:  2020-06-24       Impact factor: 2.751

3.  Clinical Significance of Ubiquitin-associated Protein 2-like in Patients With Uterine Cervical Cancer.

Authors:  Kosuke Yoshida; Hiroaki Kajiyama; Eri Inami; Satoshi Tamauchi; Yoshiki Ikeda; Nobuhisa Yoshikawa; Kimihiro Nishino; Fumi Utsumi; Kaoru Niimi; Shiro Suzuki; Kiyosumi Shibata; Akihiro Nawa; Fumitaka Kikkawa
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

4.  PQN-59 antagonizes microRNA-mediated repression during post-embryonic temporal patterning and modulates translation and stress granule formation in C. elegans.

Authors:  Colleen Carlston; Robin Weinmann; Natalia Stec; Simona Abbatemarco; Francoise Schwager; Jing Wang; Huiwu Ouyang; Collin Y Ewald; Monica Gotta; Christopher M Hammell
Journal:  PLoS Genet       Date:  2021-11-22       Impact factor: 6.020

5.  UBAP2L promotes gastric cancer metastasis by activating NF-κB through PI3K/AKT pathway.

Authors:  Ou Li; Cheng Zhao; Jian Zhang; Feng-Nan Li; Zi-Yi Yang; Shi-Lei Liu; Chen Cai; Zi-Yao Jia; Wei Gong; Yi-Jun Shu; Ping Dong
Journal:  Cell Death Discov       Date:  2022-03-19

6.  Systematic Analysis of Stress Granule Regulators-Associated Molecular Subtypes Predicts Drug Response, Immune Response, and Prognosis in Non-Small Cell Lung Cancer.

Authors:  Dan Wang; Jiangen Ao; Youwen Xiong; Xinyi Zhang; Weifang Zhang
Journal:  Front Cell Dev Biol       Date:  2022-03-30

7.  Ubiquitin Associated Protein 2-Like (UBAP2L) Overexpression in Patients with Hepatocellular Carcinoma and its Clinical Significance.

Authors:  Wei Wang; Min Zhang; Yan Peng; Jie He
Journal:  Med Sci Monit       Date:  2017-10-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.